These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 29172693)
1. Ephedrine as a lead compound for the development of new DPP-IV inhibitors. Ojeda-Montes MJ; Ardid-Ruiz A; Tomás-Hernández S; Gimeno A; Cereto-Massagué A; Beltrán-Debón R; Mulero M; Garcia-Vallvé S; Pujadas G; Valls C Future Med Chem; 2017 Dec; 9(18):2129-2146. PubMed ID: 29172693 [TBL] [Abstract][Full Text] [Related]
2. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Deng X; Han L; Zhou J; Zhang H; Li Q Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096 [TBL] [Abstract][Full Text] [Related]
3. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation. Meduru H; Wang YT; Tsai JJ; Chen YC Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951 [TBL] [Abstract][Full Text] [Related]
4. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis. Khalaf RA; Masalha D; Sabbah D Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469 [TBL] [Abstract][Full Text] [Related]
5. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling. Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Sharma M; Gupta M; Singh D; Kumar M; Kaur P Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413 [TBL] [Abstract][Full Text] [Related]
7. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285 [TBL] [Abstract][Full Text] [Related]
8. In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors. Nongonierma AB; Mooney C; Shields DC; FitzGerald RJ Peptides; 2014 Jul; 57():43-51. PubMed ID: 24793774 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859 [TBL] [Abstract][Full Text] [Related]
10. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors. Deng X; Shen J; Zhu H; Xiao J; Sun R; Xie F; Lam C; Wang J; Qiao Y; Tavallaie MS; Hu Y; Du Y; Li J; Fu L; Jiang F Bioorg Med Chem; 2018 Feb; 26(4):903-912. PubMed ID: 29373269 [TBL] [Abstract][Full Text] [Related]
11. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Li Q; Han L; Zhang B; Zhou J; Zhang H Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses. Mohanty IR; Borde M; Kumar C S; Maheshwari U Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory evaluation of Zabidi NA; Ishak NA; Hamid M; Ashari SE; Mohammad Latif MA J Enzyme Inhib Med Chem; 2021 Dec; 36(1):109-121. PubMed ID: 33249946 [TBL] [Abstract][Full Text] [Related]
17. α-Amylase and dipeptidyl peptidase-4 (DPP-4) inhibitory effects of Quek A; Kassim NK; Lim PC; Tan DC; Mohammad Latif MA; Ismail A; Shaari K; Awang K Pharm Biol; 2021 Dec; 59(1):964-973. PubMed ID: 34347568 [TBL] [Abstract][Full Text] [Related]
18. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review. Turdu G; Gao H; Jiang Y; Kabas M Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus. Kuranov SO; Tsypysheva IP; Khvostov MV; Zainullina LF; Borisevich SS; Vakhitova YV; Luzina OA; Salakhutdinov NF Bioorg Med Chem; 2018 Aug; 26(15):4402-4409. PubMed ID: 30056037 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]